Hand holding ZORYVE steroid-free cream

Actor portrayal

Hand holding ZORYVE steroid-free cream

Actor portrayal

 Itch Relief

RAPID ITCH RELIEF

RAPID, SIGNIFICANT ITCH RELIEF WITH A ONCE-DAILY, STEROID-FREE CREAM

69% of patients achieved WI-NRS Success at Week 8,
with results as early as Week 2

(% of patients achieving WI-NRS Success)1,2*

†P<0.001 vs vehicle, nominal.WEEK 2WEEK 4WEEK 6WEEK 8ZORYVE(n=447)Vehicle(n=231)54%†69%†22%20%60%†26%31%38%†
ZORYVE(n=447)Vehicle(n=231)WEEK 2WEEK 4WEEK 6WEEK 854%†60%†22%20%26%69%†31%38%†††P<0.001 vs vehicle, nominal.

Data are pooled analyses of the DERMIS-1 and DERMIS-2 studies.
*WI-NRS Success defined as a ≥4-point improvement for patients with a baseline score ≥4.
WI-NRS scale: 0 (no itch) to 10 (worst imaginable itch). WI-NRS = Worst Itch Numeric Rating Scale.

In a Phase 2 study

Itch-related sleep loss improved while on active treatment9‡

‡Based on patient-reported outcomes (PROs) data related to itch from a Phase 2b study evaluating efficacy and safety of once-daily roflumilast cream compared to vehicle for plaque psoriasis for 12 weeks. Patients were evaluated on itch-related sleep loss (IRSL) by answering a numeric scale 0 (no IRSL) to 10 (IRSL as bad as it could be) over the previous 24 hours.

ITCH IS THE MOST BOTHERSOME and frequently reported symptom of psoriasis, according to a 2012 population-based survey of over 2,700 patients with plaque psoriasis in North America and Europe.10

Study Design
See Before & After
View Safety Profile